| Type I interferons in infectious disease F McNab, K Mayer-Barber, A Sher, A Wack, A O'garra Nature Reviews Immunology 15 (2), 87-103, 2015 | 2908 | 2015 |
| Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein S Crotta, A Stilla, A Wack, A D'Andrea, S Nuti, U D'Oro, M Mosca, ... The Journal of experimental medicine 195 (1), 35-42, 2002 | 618 | 2002 |
| The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells A Seubert, E Monaci, M Pizza, DT O’Hagan, A Wack The journal of Immunology 180 (8), 5402-5412, 2008 | 547 | 2008 |
| Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes S Calabro, M Tortoli, BC Baudner, A Pacitto, M Cortese, DT O’Hagan, ... Vaccine 29 (9), 1812-1823, 2011 | 518 | 2011 |
| Guarding the frontiers: the biology of type III interferons A Wack, E Terczyńska-Dyla, R Hartmann Nature immunology 16 (8), 802-809, 2015 | 459 | 2015 |
| Type I and III interferons disrupt lung epithelial repair during recovery from viral infection J Major, S Crotta, M Llorian, TM McCabe, HH Gad, SL Priestnall, ... Science 369 (6504), 712-717, 2020 | 446 | 2020 |
| Pathogenic potential of interferon αβ in acute influenza infection S Davidson, S Crotta, TM McCabe, A Wack Nature communications 5 (1), 3864, 2014 | 438 | 2014 |
| Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia S Crotta, S Davidson, T Mahlakoiv, CJ Desmet, MR Buckwalter, ML Albert, ... PLoS pathogens 9 (11), e1003773, 2013 | 329 | 2013 |
| Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection H Aegerter, J Kulikauskaite, S Crotta, H Patel, G Kelly, EM Hessel, ... Nature immunology 21 (2), 145-157, 2020 | 310 | 2020 |
| Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection KC Bradley, K Finsterbusch, D Schnepf, S Crotta, M Llorian, S Davidson, ... Cell reports 28 (1), 245-256. e4, 2019 | 293 | 2019 |
| Safety of MF59™ adjuvant V Schultze, V D’Agosto, A Wack, D Novicki, J Zorn, R Hennig Vaccine 26 (26), 3209-3222, 2008 | 293 | 2008 |
| Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets D Piccioli, S Tavarini, E Borgogni, V Steri, S Nuti, C Sammicheli, ... Blood, The Journal of the American Society of Hematology 109 (12), 5371-5379, 2007 | 275 | 2007 |
| IFN λ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFN α treatment S Davidson, TM McCabe, S Crotta, HH Gad, EM Hessel, S Beinke, ... EMBO molecular medicine 8 (9), 1099-1112, 2016 | 272 | 2016 |
| Disease-promoting effects of type I interferons in viral, bacterial, and coinfections S Davidson, MK Maini, A Wack Journal of Interferon & Cytokine Research 35 (4), 252-264, 2015 | 254 | 2015 |
| Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers CF Houlihan, N Vora, T Byrne, D Lewer, G Kelly, J Heaney, S Gandhi, ... The Lancet 396 (10246), e6-e7, 2020 | 251 | 2020 |
| Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice A Wack, BC Baudner, AK Hilbert, I Manini, S Nuti, S Tavarini, H Scheffczik, ... Vaccine 26 (4), 552-561, 2008 | 245 | 2008 |
| The interferon landscape along the respiratory tract impacts the severity of COVID-19 B Sposito, A Broggi, L Pandolfi, S Crotta, N Clementi, R Ferrarese, S Sisti, ... Cell 184 (19), 4953-4968. e16, 2021 | 239 | 2021 |
| COVID-19 and emerging viral infections: The case for interferon lambda L Prokunina-Olsson, N Alphonse, RE Dickenson, JE Durbin, JS Glenn, ... Journal of Experimental Medicine 217 (5), e20200653, 2020 | 233 | 2020 |
| The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression V Male, I Nisoli, T Kostrzewski, DSJ Allan, JR Carlyle, GM Lord, A Wack, ... Journal of experimental medicine 211 (4), 635-642, 2014 | 225 | 2014 |
| Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 A Seubert, S Calabro, L Santini, B Galli, A Genovese, S Valentini, S Aprea, ... Proceedings of the national academy of sciences 108 (27), 11169-11174, 2011 | 221 | 2011 |
Sandra NutiHead of FACS Facility, Preclinical R&D, GSK Vaccines, Rockville, MDOverená e-mailová adresa na: gsk.com
